lazertinib,amivantamab,olaparib,osimertinib,trastuzumab deruxtecan,pembrolizumab,durvalumab
merck,yuhan corp,astrazeneca,janssen,daiichi sankyo
['pembro', 'lazertinib', 'ovarian', 'enhertu', 'tagrisso', 'lynparza', 'lung', 'pan-tumor', 'imfinzi', 'amivantamab', '$azn', 'astrazeneca']
astrazeneca ($azn) #asco23 - key data lung: tagrisso (egfr) lung: dato-dxd (trop2 adc) + pembro + chemo lung: amivantamab (bifx egfr/met) + lazertinib (egfr) pan-tumor: enhertu (her2 adc) ovarian: imfinzi (pd1) + lynparza (parp) (link to subst***ack in bio) 
Bi-Weekly Biotech Updates: Public & Private Market Updates, Company Building, Financing, Exit Strategies, and Emerging Science Trends | Current: Biotech VC